| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2021 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD STE 260 | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R43AG071335 | Evaluation of Alzheimers disease experimental small molecule therapeutics in the models of Amyotrophic lateral sclerosis | 000 | 1 | NIH | 10/15/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,548,979 ) |
| | 2024 | 2024 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD STE 260 | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R43NS135837 | Novel Product Formulation toModulate Alpha7 Nicotinic Receptors for Therapy in Stroke Recovery | 000 | 1 | NIH | 5/28/2024 | $550,864 |
| | 2024 | 2024 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD STE 260 | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R44DK129071 | Candidate selection of a LPAR1 antagonist for therapeutic application in NASH | 001 | 3 | NIH | 7/11/2024 | $1,041,548 |
| | 2024 | 2023 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD STE 260 | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R44DK129071 | Candidate selection of a LPAR1 antagonist for therapeutic application in NASH | 000 | 2 | NIH | 6/24/2024 | $0 |
| | 2024 | 2022 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD STE 260 | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R44DK127879 | Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy | 000 | 2 | NIH | 5/2/2024 | $0 |
| | 2024 | 2022 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD STE 260 | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R44MH115529 | Novel therapy for Fragile X syndrome | 000 | 4 | NIH | 6/4/2024 | $0 |
| | 2024 | 2021 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD STE 260 | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R43DK129071 | Lead candidate identification of LPAR1 antagonists for therapeutic application in NASH | 000 | 1 | NIH | 2/26/2024 | $0 |
| | 2024 | 2021 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD STE 260 | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | U18DA052553 | Novel modulators of ÃÂñ7 nAChRs as treatments for nicotine reward | 000 | 1 | NIH | 10/13/2023 | $0 |
| | 2024 | 2020 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD STE 260 | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R44DK092005 | Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis | 000 | 6 | NIH | 1/16/2024 | $0 |
| | 2024 | 2020 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD STE 260 | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R44AG043243 | Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease | 000 | 4 | NIH | 9/9/2024 | -$43,433 |
|
| Issue Date FY: 2023 ( Subtotal = $1,740,237 ) |
| | 2023 | 2023 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R43DK134242 | New Therapy for the Treatment of Primary Biliary Cholangitis. | 000 | 1 | NIH | 5/31/2023 | $448,110 |
| | 2023 | 2023 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R44DK129071 | Candidate selection of a LPAR1 antagonist for therapeutic application in NASH | 000 | 2 | NIH | 8/23/2023 | $971,732 |
| | 2023 | 2021 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R43AG071335 | Evaluation of Alzheimers disease experimental small molecule therapeutics in the models of Amyotrophic lateral sclerosis | 000 | 1 | NIH | 5/25/2023 | $0 |
| | 2023 | 2021 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R43DK129071 | Lead candidate identification of LPAR1 antagonists for therapeutic application in NASH | 000 | 1 | NIH | 8/15/2023 | $0 |
| | 2023 | 2020 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R43HL150986 | Novel agents for idiopathic pulmonary fibrosis | 000 | 1 | NIH | 11/10/2022 | $0 |
| | 2023 | 2020 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R44AG043243 | Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease | 000 | 4 | NIH | 4/7/2023 | $320,495 |
| | 2023 | 2020 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R44AG043243 | Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease | 001 | 4 | NIH | 6/2/2023 | $0 |
| | 2023 | 2019 | EPIGEN BIOSCIENCES INC | 6725 MESA RIDGE RD | SAN DIEGO | CA | 92121-3938 | SAN DIEGO | USA | R43DE029379 | Therapeutic in Situ Analgesic Implant for improved Oral-Facial Post-Operative Pain Outcomes | 000 | 1 | NIH | 7/18/2023 | -$100 |
|
| Issue Date FY: 2022 ( Subtotal = $2,147,907 ) |
| | 2022 | 2022 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R44MH115529 | Novel therapy for Fragile X syndrome | 000 | 4 | NIH | 4/20/2022 | $1,157,216 |
| | 2022 | 2022 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R44DK127879 | Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy | 000 | 2 | NIH | 5/6/2022 | $990,691 |
| | 2022 | 2021 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R43DK129071 | Lead candidate identification of LPAR1 antagonists for therapeutic application in NASH | 000 | 1 | NIH | 12/15/2021 | $0 |
| | 2022 | 2020 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R44DK092005 | Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis | 000 | 6 | NIH | 11/2/2021 | $0 |
| | 2022 | 2020 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R44AG043243 | Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease | 000 | 4 | NIH | 4/8/2022 | $0 |
| | 2022 | 2020 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R44DK092005 | Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis | 001 | 6 | NIH | 6/24/2022 | $0 |
| | 2022 | 2020 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R43DK123920 | Assessment of a selective kinase inhibitor in pre-clinical models of NASH | 000 | 1 | NIH | 2/16/2022 | $0 |
| | 2022 | 2018 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R43AR072546 | New Approach to Atopic Dermatitis | 000 | 1 | NIH | 2/17/2022 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $3,125,058 ) |
| | 2021 | 2021 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R43AG071335 | Evaluation of Alzheimers disease experimental small molecule therapeutics in the models of Amyotrophic lateral sclerosis | 000 | 1 | NIH | 5/19/2021 | $449,984 |
| | 2021 | 2021 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | U18DA052553 | Novel modulators of ÃÂñ7 nAChRs as treatments for nicotine reward | 000 | 1 | NIH | 12/3/2020 | $192,907 |
| | 2021 | 2021 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R43DK129071 | Lead candidate identification of LPAR1 antagonists for therapeutic application in NASH | 000 | 1 | NIH | 9/20/2021 | $397,398 |
| | 2021 | 2021 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R44MH115529 | Novel therapy for Fragile X syndrome | 000 | 3 | NIH | 4/12/2021 | $998,958 |
| | 2021 | 2021 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R44MH115529 | Novel therapy for Fragile X syndrome | 001 | 3 | NIH | 8/20/2021 | $50,000 |
| | 2021 | 2021 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R44DK127879 | Selection of a lead LPAR1 antagonist for treatment of diabetic neuropathy | 000 | 1 | NIH | 5/20/2021 | $1,035,811 |
| | 2021 | 2020 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R43DK123920 | Assessment of a selective kinase inhibitor in pre-clinical models of NASH | 000 | 1 | NIH | 3/24/2021 | $0 |
| | 2021 | 2019 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R43DE029379 | Therapeutic in Situ Analgesic Implant for improved Oral-Facial Post-Operative Pain Outcomes | 000 | 1 | NIH | 9/16/2021 | $0 |
| | 2021 | 2018 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R43DK117758 | Assessment of LPA1R antagonists in animal models of NASH | 000 | 1 | NIH | 3/11/2021 | $0 |
| | 2021 | 2018 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R41MH115529 | Novel therapy for Fragile X syndrome | 000 | 2 | NIH | 2/23/2021 | $0 |
| | 2021 | 2018 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R43AR072546 | New Approach to Atopic Dermatitis | 000 | 1 | NIH | 10/19/2020 | $0 |
| | 2021 | 2017 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R41NS098903 | Novel Treatment for Traumatic Brain Injury | 000 | 1 | NIH | 2/14/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $2,677,118 ) |
| | 2020 | 2020 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R44AG043243 | Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease | 001 | 4 | NIH | 3/23/2020 | $1,002,264 |
| | 2020 | 2020 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R43HL150986 | Novel agents for idiopathic pulmonary fibrosis | 000 | 1 | NIH | 4/30/2020 | $299,983 |
| | 2020 | 2020 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R44DK092005 | Development of a novel therapeutic for the treatment of diabetic nephropathy and renal fibrosis | 000 | 6 | NIH | 6/2/2020 | $999,838 |
| | 2020 | 2020 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R43DK123920 | Assessment of a selective kinase inhibitor in pre-clinical models of NASH | 000 | 1 | NIH | 7/30/2020 | $375,033 |
| | 2020 | 2019 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R43DE029379 | Therapeutic in Situ Analgesic Implant for improved Oral-Facial Post-Operative Pain Outcomes | 000 | 1 | NIH | 1/17/2020 | $0 |
| | 2020 | 2019 | EPIGEN BIOSCIENCES INC. | 10225 BARNES CANYON RD, STE A104 | SAN DIEGO | CA | 92121-2734 | SAN DIEGO | USA | R44AG043243 | Lead optimization and development of novel targeted small molecule therapeutics for Alzheimers disease | 000 | 3 | NIH | 11/15/2019 | $0 |
|
|
